Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14145-50.

Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).

Author information

1
Department of Physiology, Institute of Biomedicine, and Department of Clinical Chemistry, University of Helsinki, FIN-00014, Helsinki, Finland.

Abstract

Modification by SUMO-1 is proposed to play a role in protein targeting and/or stability. The SUMO-1-conjugating enzyme Ubc9 interacts with androgen receptor (AR), a ligand-activated transcription factor belonging to the steroid receptor superfamily. We show here that AR is covalently modified by SUMO-1 (sumoylated) in an androgen-enhanced fashion and identify the principal acceptor site in the N-terminal domain of AR. Substitutions of sumoylated Lys residues enhanced transcriptional activity of AR without influencing its transrepressing activity. Interestingly, the same Lys residues form the cores of the recently described transcriptional synergy control motifs in AR [Iñiguez-Lluhi, J. A. & Pearce, D. (2000) Mol. Cell. Biol. 20, 6040-6050]. These motifs, which match perfectly with the sumoylation consensus sequence, are also present in the N-terminal domains of glucocorticoid, mineralocorticoid, and progesterone receptor. Taken together, our data suggest that reversible sumoylation is a mechanism for regulation of steroid receptor function.

PMID:
11121022
PMCID:
PMC18885
DOI:
10.1073/pnas.97.26.14145
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center